EUbOPEN: Enabling and unlocking biology in the OPEN
EUbOPEN logo


Start Date
End Date
IMI2 - Call 17
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
27 935 000
EFPIA in kind
23 777 950
Associated Partners
6 445 380
5 433 462
Total Cost
63 591 792


When developing new medicines, scientists need to understand the underlying causes of disease. To do that, they need to be able to study in detail the role of the different proteins involved in the disease. However, that requires chemical compounds capable of altering or blocking the action of individual proteins.

The goal of EUbOPEN is to develop high quality chemical tool compounds for 1 000 human proteins. This represents around a third of the ‘druggable’ proteins in the human body. The project will test the new tools in the areas of immunology, oncology and neuroscience.

The project will make the tools, plus the accompanying data and protocols, openly available to the entire research community without restrictions on use.

By the end of the project, the EUbOPEN team will have created the largest and most deeply characterised collection of chemical modulators of protein function that is also openly accessible. Researchers in academia and industry alike will therefore be able to use the tools to study diseases, and identify proteins that play a key role in disease development and so could be targeted by drugs. The tools will also help scientists to design drugs capable of blocking specific proteins involved in diseases.

Participants Show participants on map

EFPIA companies
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany
  • Institut De Recherches Servier, Suresnes, France
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Leiden, Leiden, Netherlands
  • Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Stiftung, Frankfurt, Germany
  • Eidgenoessische Technische Hochschule Zuerich, Zurich, Switzerland
  • European Molecular Biology Laboratory, Heidelberg, Germany
  • Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung Ev, München, Germany
  • Johann Wolfgang Goethe-Universitaet Frankfurt Am Main, Frankfurt am Main, Germany
  • Karolinska Institutet, Stockholm, Sweden
  • Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany
  • Structural Genomics Consortium Lbg, London, United Kingdom
  • The Governing Council Of The University Of Toronto, Toronto, Canada
  • The University Of North Carolina At Chapel Hill, Chapel Hill, United States
  • University Of Dundee, Dundee, United Kingdom
  • University of Oxford, Oxford, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • X-Chem Inc, Waltham, MA, United States
Associated partners
  • Diamond Light Source Limited, Didcot, United Kingdom
  • Kungliga Tekniska Hoegskolan, Stockholm, Sweden
  • Ontario Institute for Cancer Research, Toronto, Ontario, Canada
  • Royal Institution For The Advancement Of Learning Mcgill University, Montreal, Canada
Project coordinator
Stefan Knapp
Johann Wolfgang Goethe-Universitaet Frankfurt Am Main